Here is Think IP Strategy’s weekly selection of top Pharma & Biotech intellectual property news breaking in the blogosphere and internet.

Highlights this week included:

US Supreme Court to revisit patentable subject matter eligibility of medical diagnostic methods:  Mayo v Prometheus (Patently-O) (Patent Baristas) (PharmaPatents) (IPBiz) (Patent Law Practice Center)

Baytril (Enrofloxacin) – US: In a rare move, District Court extends 30-month stay on FDA ANADA approval: Bayer Healthcare v Norbrook (FDA Law Blog)

Europe seizure of generic drugs: Lilly settles with Indian generics (Generic Pharmaceuticals and IP)

Please join the discussion by adding your comments on any of these stories, and please do let us know if you think we’ve missed something important, or if there is a source you think should be monitored.

General

New IP resource for Pharma, Biotech and Chem – Finding the right model for Research & Development Collaboration (IP Think Tank)

Drug prices: Food vs. medicine – A difficult choice for some (profitability through simplicity)

White House and European Commission trade official oppose waiver of drug patents for Least Developed Countries (LDCs) (Knowledge Ecology International)

From SPC Blog to SPC textbook (The SPC Blog)

EU: Europe seizure of generic drugs: Lilly settles with Indian generics (Generic Pharmaceuticals and IP)

EU: CJEU – May an SPC be granted having a negative duration? A-G’s opinion published – Merck & Co Inc. v Deutsches Patent- und Markenamt (EPLAW) (The SPC Blog)

US: Supreme Court to revisit patentable subject matter eligibility of medical diagnostic methods:  Mayo v Prometheus (Patently-O) (Patent Baristas) (PharmaPatents) (IPBiz) (Patent Law Practice Center)

US: Intellectual property problems for personalized medicine (BIOtechNow)

US: Supreme Court ruling in Stanford v Roche (IPKat) (IPKat)

US: Manager’s Amendment (and others) to H.R. 1249 — Human patenting (Patent Docs)

US: “Gene patents” stifle research? (BIOtechNow)

US: Manager’s Amendment (and others) to H.R. 1249 — Second opinions in genetic diagnostic testing (Patent Docs)

US: AMA, ACLU and their friends oppose (Leahy-Smith) America Invents Act (Patent Docs)

US: Kaneka files new 337 complaint regarding Certain Coenzyme Q10 Products (ITC 337 Law Blog)

Products

Baytril (Enrofloxacin) – US: In a rare move, District Court extends 30-month stay on FDA ANADA approval: Bayer Healthcare v Norbrook (FDA Law Blog)

Cialis (Tadalafil) – Israel: Opposition withdrawn but Israel Patent Office refuses patent anyway (IP Factor)

Co-Diovan (Valsartan / HCTZ) – Belgium: First Belgian decision on SPC’s coverage of combination products (Kluwer Patent Blog)

Combigan (Brimonidine / Timolol) – US: Allergan and Hi-Tech settle Combigan patent dispute (Patent Docs)

Focalin (Dexmethylphenidate) – US: Novartis and Sun settle Focalin patent suit (Patent Docs)

Glumetza (Metformin) – US: Depomed files patent infringement lawsuit against Sun Pharmaceutical Industries (GenericsWeb)

Lovaza (Omega-3-acid ethyl esters) – US: Pronova BioPharma receives Lovaza paragraph IV notice letter from Endo (GenericsWeb)

Neurontin (Gabapentin) – US: Antitrust sanctions upheld against Pfizer in Neurontin case (Patent Docs)

Pataday (Olopatadine) – US: Alcon files patent infringement complaint against Watson Laboratories in response to Para IV certification (Patent Docs)

Seasonique (Levonorgestrel / Ethinyl estradiol) – US: Watson confirms court decision rejecting Teva’s motion to prevent launch of generic Seasonique (GenericsWeb)

Silenor (Doxepin) – US: Somaxon Pharmaceuticals files patent infringement suit against Zydus, Cadila in response to ANDA filing (Patent Docs)

Tenofovir  Disoproxil – India: TD opposition and rejection order (Indian Patent Oppositions)

Tenofovir  Disoproxil Fumarate – India: TDF opposition and patent status (Indian Patent Oppositions)

Xalatan (Latanoprost) – Italy: Pfizer offers commitments to settle case at the Italian Competition Authority (Kluwer Patent Blog)

Zidovudine / Lamivudine – India: GSK opposition to AZT/3TC (Indian Patent Oppositions)